324 related articles for article (PubMed ID: 27704226)
1. Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II-III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance).
Golshan M; Cirrincione CT; Sikov WM; Carey LA; Berry DA; Overmoyer B; Henry NL; Somlo G; Port E; Burstein HJ; Hudis C; Winer E; Ollila DW;
Breast Cancer Res Treat; 2016 Nov; 160(2):297-304. PubMed ID: 27704226
[TBL] [Abstract][Full Text] [Related]
2. The impact of neoadjuvant systemic therapy on breast conservation rates in patients with HER2-positive breast cancer: Surgical results from a phase II randomized controlled trial.
Yamaguchi T; Hozumi Y; Sagara Y; Takahashi M; Yoneyama K; Fujisawa T; Osumi S; Akabane H; Nishimura R; Mieno MN; Mukai H
Surg Oncol; 2021 Mar; 36():51-55. PubMed ID: 33310293
[TBL] [Abstract][Full Text] [Related]
3. Impact of neoadjuvant chemotherapy in stage II-III triple negative breast cancer on eligibility for breast-conserving surgery and breast conservation rates: surgical results from CALGB 40603 (Alliance).
Golshan M; Cirrincione CT; Sikov WM; Berry DA; Jasinski S; Weisberg TF; Somlo G; Hudis C; Winer E; Ollila DW;
Ann Surg; 2015 Sep; 262(3):434-9; discussion 438-9. PubMed ID: 26222764
[TBL] [Abstract][Full Text] [Related]
4. Breast Conservation After Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: Surgical Results From the BrighTNess Randomized Clinical Trial.
Golshan M; Loibl S; Wong SM; Houber JB; O'Shaughnessy J; Rugo HS; Wolmark N; McKee MD; Maag D; Sullivan DM; Metzger-Filho O; Von Minckwitz G; Geyer CE; Sikov WM; Untch M
JAMA Surg; 2020 Mar; 155(3):e195410. PubMed ID: 31913413
[TBL] [Abstract][Full Text] [Related]
5. Conversion rate from mastectomy to breast conservation after neoadjuvant dual target therapy for HER2-positive breast cancer in the Asian population.
Chang YK; Co M; Kwong A
Breast Cancer; 2020 May; 27(3):456-463. PubMed ID: 31916189
[TBL] [Abstract][Full Text] [Related]
6. Locoregional Control According to Breast Cancer Subtype and Response to Neoadjuvant Chemotherapy in Breast Cancer Patients Undergoing Breast-conserving Therapy.
Swisher SK; Vila J; Tucker SL; Bedrosian I; Shaitelman SF; Litton JK; Smith BD; Caudle AS; Kuerer HM; Mittendorf EA
Ann Surg Oncol; 2016 Mar; 23(3):749-56. PubMed ID: 26511263
[TBL] [Abstract][Full Text] [Related]
7. Impact of neoadjuvant chemotherapy and pathological complete response on eligibility for breast-conserving surgery in patients with early breast cancer: A meta-analysis.
Criscitiello C; Golshan M; Barry WT; Viale G; Wong S; Santangelo M; Curigliano G
Eur J Cancer; 2018 Jul; 97():1-6. PubMed ID: 29734046
[TBL] [Abstract][Full Text] [Related]
8. Axillary Management of Stage II/III Breast Cancer in Patients Treated with Neoadjuvant Systemic Therapy: Results of CALGB 40601 (HER2-Positive) and CALGB 40603 (Triple-Negative).
Ollila DW; Cirrincione CT; Berry DA; Carey LA; Sikov WM; Hudis CA; Winer EP; Golshan M
J Am Coll Surg; 2017 Apr; 224(4):688-694. PubMed ID: 28089784
[TBL] [Abstract][Full Text] [Related]
9. Surgical Treatment After Neoadjuvant Systemic Therapy in Young Women With Breast Cancer: Results From a Prospective Cohort Study.
Kim HJ; Dominici L; Rosenberg SM; Zheng Y; Pak LM; Poorvu PD; Ruddy KJ; Tamimi R; Schapira L; Come SE; Peppercorn J; Borges VF; Warner E; Vardeh H; Collins LC; Gaither R; King TA; Partridge AH
Ann Surg; 2022 Jul; 276(1):173-179. PubMed ID: 33378304
[TBL] [Abstract][Full Text] [Related]
10. A prospective trial of preoperative chemotherapy in resectable breast cancer: predictors of breast-conservation therapy feasibility.
Newman LA; Buzdar AU; Singletary SE; Kuerer HM; Buchholz T; Ames FC; Ross MI; Hunt KK
Ann Surg Oncol; 2002 Apr; 9(3):228-34. PubMed ID: 11923128
[TBL] [Abstract][Full Text] [Related]
11. Do MRI and mammography reliably identify candidates for breast conservation after neoadjuvant chemotherapy?
Jochelson MS; Lampen-Sachar K; Gibbons G; Dang C; Lake D; Morris EA; Morrow M
Ann Surg Oncol; 2015 May; 22(5):1490-5. PubMed ID: 25777093
[TBL] [Abstract][Full Text] [Related]
12. Impact of Neoadjuvant Paclitaxel/Trastuzumab/Pertuzumab on Breast Tumor Downsizing for Patients with HER2+ Breast Cancer: Single-Arm Prospective Clinical Trial.
Weiss A; Li T; Desai NV; Tung NM; Poorvu PD; Partridge AH; Nakhlis F; Dominici L; Sinclair N; Spring LM; Faggen M; Constantine M; Krop IE; DeMeo M; Wrabel E; Alberti J; Chikarmane S; Tayob N; King TA; Tolaney SM; Winer EP; Mittendorf EA; Waks AG
J Am Coll Surg; 2023 Aug; 237(2):247-256. PubMed ID: 37194964
[TBL] [Abstract][Full Text] [Related]
13. Conservative surgery after neoadjuvant chemotherapy in patients with operable breast cancer.
Franceschini G; Di Leone A; Natale M; Sanchez MA; Masett R
Ann Ital Chir; 2018; 89():290. PubMed ID: 30352955
[TBL] [Abstract][Full Text] [Related]
14. Breast-Conserving Therapy in Patients with cT3 Breast Cancer with Good Response to Neoadjuvant Systemic Therapy Results in Excellent Local Control: A Comprehensive Cancer Center Experience.
van der Noordaa MEM; Ioan I; Rutgers EJ; van Werkhoven E; Loo CE; Voorthuis R; Wesseling J; van Urk J; Wiersma T; Dezentje V; Vrancken Peeters MTFD; van Duijnhoven FH
Ann Surg Oncol; 2021 Nov; 28(12):7383-7394. PubMed ID: 33978889
[TBL] [Abstract][Full Text] [Related]
15. How Often Does Modern Neoadjuvant Chemotherapy Downstage Patients to Breast-Conserving Surgery?
Petruolo O; Sevilimedu V; Montagna G; Le T; Morrow M; Barrio AV
Ann Surg Oncol; 2021 Jan; 28(1):287-294. PubMed ID: 32514804
[TBL] [Abstract][Full Text] [Related]
16. The percentage of residual DCIS in patients diagnosed with primary invasive breast cancer treated with neoadjuvant systemic therapy: A nationwide retrospective study.
Ploumen RAW; Keymeulen KBMI; Kooreman LFS; van Kuijk SMJ; Siesling S; Smidt ML; van Nijnatten TJA
Eur J Surg Oncol; 2022 Jan; 48(1):60-66. PubMed ID: 34756527
[TBL] [Abstract][Full Text] [Related]
17. Pathologic Complete Response Rates After Neoadjuvant Pertuzumab and Trastuzumab with Chemotherapy in Early Stage HER2-Positive Breast Cancer - Increasing Rates of Breast Conserving Surgery: A Real-World Experience.
Boér K; Kahán Z; Landherr L; Csőszi T; Máhr K; Ruzsa Á; Horváth Z; Budai B; Rubovszky G
Pathol Oncol Res; 2021; 27():1609785. PubMed ID: 34257621
[No Abstract] [Full Text] [Related]
18. Which eligible breast conservation patients choose mastectomy in the setting of newly diagnosed breast cancer?
Adkisson CD; Bagaria SP; Parker AS; Bray JM; Gibson T; Thomas CS; Heckman MG; McLaughlin SA
Ann Surg Oncol; 2012 Apr; 19(4):1129-36. PubMed ID: 21975859
[TBL] [Abstract][Full Text] [Related]
19. Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy.
Caudle AS; Yu TK; Tucker SL; Bedrosian I; Litton JK; Gonzalez-Angulo AM; Hoffman K; Meric-Bernstam F; Hunt KK; Buchholz TA; Mittendorf EA
Breast Cancer Res; 2012 May; 14(3):R83. PubMed ID: 22621334
[TBL] [Abstract][Full Text] [Related]
20. Impact of neoadjuvant chemotherapy on surgical outcomes among patients with hormone receptor positive breast cancer.
Hage AN; Capriccioso C; Brennan J; Heiden B; Zheutlin A; Sabel MS
J Surg Oncol; 2017 Nov; 116(6):665-670. PubMed ID: 28672101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
